Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter
  • Published:

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

Nature volume 494, pages 251–255 (2013)Cite this article

Subjects

This article has been updated

Abstract

Mutational activation of BRAF is the most prevalent genetic alteration in human melanoma, with ≥50% of tumours expressing the BRAF(V600E) oncoprotein1,2. Moreover, the marked tumour regression and improved survival of late-stage BRAF-mutated melanoma patients in response to treatment with vemurafenib demonstrates the essential role of oncogenic BRAF in melanoma maintenance3,4. However, as most patients relapse with lethal drug-resistant disease, understanding and preventing mechanism(s) of resistance is critical to providing improved therapy5. Here we investigate the cause and consequences of vemurafenib resistance using two independently derived primary human melanoma xenograft models in which drug resistance is selected by continuous vemurafenib administration. In one of these models, resistant tumours show continued dependency on BRAF(V600E)→MEK→ERK signalling owing to elevated BRAF(V600E) expression. Most importantly, we demonstrate that vemurafenib-resistant melanomas become drug dependent for their continued proliferation, such that cessation of drug administration leads to regression of established drug-resistant tumours. We further demonstrate that a discontinuous dosing strategy, which exploits the fitness disadvantage displayed by drug-resistant cells in the absence of the drug, forestalls the onset of lethal drug-resistant disease. These data highlight the concept that drug-resistant cells may also display drug dependency, such that altered dosing may prevent the emergence of lethal drug resistance. Such observations may contribute to sustaining the durability of the vemurafenib response with the ultimate goal of curative therapy for the subset of melanoma patients with BRAF mutations.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Resistance to vemurafenib in a primary human melanoma xenograft model.
Figure 2: Resistant tumours show increased BRAF(V600E) expression.
Figure 3: Vemurafenib-resistant tumour cells require continuous exposure to vemurafenib.
Figure 4: Intermittent dosing of vemurafenib can be exploited to forestall the development of drug resistance in vivo.

Similar content being viewed by others

Change history

  • 13 February 2013

    The y axis label in Fig. 3c was corrected.

References

  1. Fecher, L. A., Amaravadi, R. K. & Flaherty, K. T. The MAPK pathway in melanoma. Curr. Opin. Oncol. 20, 183–189 (2008)

    Article  CAS  Google Scholar 

  2. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002)

    Article  ADS  CAS  Google Scholar 

  3. Sosman, J. A. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707–714 (2012)

    Article  CAS  Google Scholar 

  4. Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010)

    Article  ADS  CAS  Google Scholar 

  5. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010)

    Article  CAS  Google Scholar 

  6. Nazarian, R. et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468, 973–977 (2010)

    Article  ADS  CAS  Google Scholar 

  7. Wagle, N. et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. 29, 3085–3096 (2011)

    Article  CAS  Google Scholar 

  8. Poulikakos, P. I. et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480, 387–390 (2011)

    Article  ADS  CAS  Google Scholar 

  9. Shi, H. et al. Melanoma whole-exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nature Commun. 3, 724 (2012)

    Article  ADS  Google Scholar 

  10. Bennett, D. C. How to make a melanoma: what do we know of the primary clonal events? Pigment Cell Melanoma Res. 21, 27–38 (2008)

    Article  CAS  Google Scholar 

  11. Petti, C. et al. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity. Cancer Res. 66, 6503–6511 (2006)

    Article  CAS  Google Scholar 

  12. Zhu, J., Woods, D., McMahon, M. & Bishop, J. M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12, 2997–3007 (1998)

    Article  CAS  Google Scholar 

  13. Woods, D. et al. Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17, 5598–5611 (1997)

    Article  CAS  Google Scholar 

  14. Marshall, C. J. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal regulated kinase activation. Cell 80, 179–185 (1995)

    Article  CAS  Google Scholar 

  15. Johannessen, C. M. et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468, 968–972 (2010)

    Article  ADS  CAS  Google Scholar 

  16. Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683–695 (2010)

    Article  CAS  Google Scholar 

  17. Tap, W. D. et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia 12, 637–649 (2010)

    Article  CAS  Google Scholar 

  18. Hoeflich, K. P. et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 66, 999–1006 (2006)

    Article  CAS  Google Scholar 

  19. Hingorani, S. R., Jacobetz, M. A., Robertson, G. P., Herlyn, M. & Tuveson, D. A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63, 5198–5202 (2003)

    CAS  PubMed  Google Scholar 

  20. Neyns, B., Seghers, A. C., Wilgenhof, S. & Lebbe, C. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res. 22, 466–472 (2012)

    Article  Google Scholar 

  21. Greaves, M. & Maley, C. C. Clonal evolution in cancer. Nature 481, 306–313 (2012)

    Article  ADS  CAS  Google Scholar 

  22. Chmielecki, J. et al. EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. J. Thorac. Oncol. 7, 434–442 (2012)

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the members of the Novartis Institutes for BioMedical Reseach (NIBR) Pharmacology department for technical support, comments and discussions during the course of this work. We thank C. Voliva, N. Aziz and E. Collisson for discussions. We thank B. Weisburd and the rest of the NIBR Bioinformatics department for assistance with exome sequencing data analysis. We thank S. Kaufman for sharing her knowledge of cell-based assays. We thank V. Marsh, N. Rosen, P. Poulikakos and D. Solit for providing additional advice and reagents. M.D.T. was supported by an NIBR Presidential Postdoctoral Fellowship. M.M. acknowledges support from the Melanoma Research Alliance and the National Cancer Institute (R01-CA176839). A.S.L. was supported by a National Research Service Award T32 training grant HL007185.

Author information

Authors and Affiliations

  1. Novartis Institutes for Biomedical Research, Emeryville, 94608, California, USA

    Meghna Das Thakur, Fernando Salangsang, Nancy K. Pryer & Darrin D. Stuart

  2. Helen Diller Family Comprehensive Cancer Center & Department of Cellular & Molecular Pharmacology, University of California San Francisco, California, 94143-0128, USA

    Allison S. Landman & Martin McMahon

  3. Novartis Institutes for Biomedical Research, Cambridge, 02139, Massachusetts, USA

    William R. Sellers

  4. Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091 Zürich, Switzerland,

    Mitchell P. Levesque & Reinhard Dummer

Authors
  1. Meghna Das Thakur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fernando Salangsang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Allison S. Landman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. William R. Sellers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Nancy K. Pryer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mitchell P. Levesque
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Reinhard Dummer
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Martin McMahon
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Darrin D. Stuart
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.D.T., M.M. and D.D.S. designed all experiments. M.D.T. performed in vivo and in vitro experiments and collected data. M.D.T., M.M. and D.D.S. analysed data, wrote the paper and guided the manuscript through review. F.S. assisted in performing in vivo experiments. A.S.L. carried out the clonogenic assay with the SK-Mel-239-C3 cells. M.P.L. and R.D. provided the human patient biopsy samples, and R.D. assisted with data analysis and interpretation. W.R.S. and N.K.P. provided input on the experimental approach and on the manuscript. M.M. and D.D.S. are co-senior authors of this manuscript.

Corresponding authors

Correspondence to Martin McMahon or Darrin D. Stuart.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Information

This file contains Supplementary Figures 1-6 and Supplementary Table 1. (PDF 416 kb)

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Das Thakur, M., Salangsang, F., Landman, A. et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 494, 251–255 (2013). https://doi.org/10.1038/nature11814

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nature11814

This article is cited by

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing